SCHEMBL275244

SCHEMBL275244

C[C@H](O)[C@@H](O)[C@H](N)CC=O

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
PAX8 Q06710 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7089370 1.00 PAX8 (0.31) PAX8
SCHEMBL11587168 1.00 PAX8 (0.31) PAX8
SCHEMBL11372719 1.00 PAX8 (0.31) PAX8
SCHEMBL11375580 1.00 PAX8 (0.31) PAX8
SCHEMBL7148697 1.00 PAX8 (0.31) PAX8
SCHEMBL272883 1.00 PAX8 (0.31) PAX8
SCHEMBL8528219 1.00 PAX8 (0.31) PAX8
Hydrochloric Acid SCHEMBL11424213 0.98 PAX8 (0.30) PAX8
SCHEMBL30685396 0.81
SCHEMBL4001228 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 656 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9200026-B2 Antibacterial agents MERCK SHARP & DOHME CORP. (US) 2015-12-01 US claimed
US-20140073589-A1 Amphetamine Prodrugs SHIRE AG (CH) 2014-03-13 US claimed
WO-2014002039-A1 AMPHETAMINE PRODRUGS SHIRE AG (CH) 2014-01-03 WO claimed
EP-1628986-B1 SYNTHESIS OF HIGH MOLECULAR WEIGHT IRON-SACCHARIDIC COMPLEXES CHROMACEUTICAL ADVANCED TECH (US) 2013-04-24 EP claimed
US-7964568-B2 Controlling temperature and pH while complexing CHROMACEUTICAL ADVANCED TECHNOLOGIES, INC. (US) 2011-06-21 US claimed
US-7538092-B2 Pharmaceutically active oligosaccharide conjugates FRESENIUS KABI DEUTSCHLAND GMBH (DE) 2009-05-26 US claimed
EP-1549350-B1 PHARMACEUTICALLY ACTIVE OLIGOSACCHARIDE CONJUGATES FRESENIUS KABI DE GMBH (DE) 2008-09-24 EP claimed
CN-1798754-A Synthesis of high molecular weight iron-saccharidic complexes CHROMACEUTICAL ADVANCED TECH (US) 2006-07-05 CN claimed
US-20060100163-A1 Pharmaceutically active oligosaccharide conjugates FRESENIUS KABI DEUTSCHLAND GMBH (DE) 2006-05-11 US claimed
EP-1628986-A2 SYNTHESIS OF HIGH MOLECULAR WEIGHT IRON-SACCHARIDIC COMPLEXES Chromaceutical Advanced Technologies, Inc. (US) 2006-03-01 EP claimed
US-6150325-A FOR TREATMENT OF ARTHRITIS, ASTHMA, INFLAMMATIONS, TUMORAL GROWTH, GASTROINTESTINAL HYPERMOTILITY, HUNTINGTON'S DISEASE, NEURITIS, NEURALGIA, HEMICRANIA, HYPERTENSION, URINARY INCONTINENCE, URTICARIA A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L. (IT) 2000-11-21 US claimed
EP-0971716-A1 BIS-ANTHRACYCLINES WITH HIGH ACTIVITY AGAINST DOXORUBICIN RESISTANT TUMORS Priebe, Waldemar (US) 2000-01-19 EP claimed
EP-0971716-A4 BIS-ANTHRACYCLINES WITH HIGH ACTIVITY AGAINST DOXORUBICIN RESISTANT TUMORS PRIEBE WALDEMAR (US) 2000-01-19 EP claimed
WO-1999058543-A1 NEW N-ALKYLOXYCARBONYL DERIVATIVES OF MONOSACCHARIDES L-ACOSAMINE AND L-DAUNOSAMINE INSTYTUT FARMACEUTYCZNY (PL) 1999-11-18 WO claimed
US-5874412-A ANTICANCER AGENTS PRIEBE WALDEMAR (US) 1999-02-23 US claimed
CN-1183786-A Bicyclic tachykinins antagonists, preparation thereof and their use in autagonistes composition MENARINI FARMA IND (IT) 1998-06-03 CN claimed
EP-0815126-A1 BICYCLIC TACHYKININS ANTAGONISTS, PREPARATION THEREOF AND THEIR USE IN PHARMACEUTICAL COMPOSITION A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L. (IT) 1998-01-07 EP claimed
WO-1997034612-A1 BIS-ANTHRACYCLINES WITH HIGH ACTIVITY AGAINST DOXORUBICIN RESISTANT TUMORS PRIEBE WALDEMAR (US) 1997-09-25 WO claimed
WO-1996028467-A1 BICYCLIC TACHYKININS ANTAGONISTS, PREPARATION THEREOF AND THEIR USE IN PHARMACEUTICAL COMPOSITION A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L. (IT) 1996-09-19 WO claimed
WO-1995012588-A1 ANTINEOPLASTIC HETERONAPHTHOQUINONES BIOCHEM PHARMA INC. (CA) 1995-05-11 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140073589-A1 Amphetamine Prodrugs SLC6A2, SLC6A3, TAAR5 PAX8 3868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.